CorMedix Inc. (CRMD): Price and Financial Metrics

CorMedix Inc. (CRMD): $3.80

0.01 (-0.26%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add CRMD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#360 of 360

in industry

CRMD Price/Volume Stats

Current price $3.80 52-week high $6.09
Prev. close $3.81 52-week low $2.57
Day low $3.64 Volume 447,600
Day high $3.88 Avg. volume 444,298
50-day MA $3.37 Dividend yield N/A
200-day MA $3.77 Market Cap 208.29M

CRMD Stock Price Chart Interactive Chart >

CRMD POWR Grades

  • CRMD scores best on the Sentiment dimension, with a Sentiment rank ahead of 55.44% of US stocks.
  • CRMD's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • CRMD ranks lowest in Quality; there it ranks in the 3rd percentile.

CRMD Stock Summary

  • The ratio of debt to operating expenses for CORMEDIX INC is higher than it is for about just 5.88% of US stocks.
  • CRMD's price/sales ratio is 6,588.07; that's higher than the P/S ratio of 99.93% of US stocks.
  • As for revenue growth, note that CRMD's revenue has grown -67.75% over the past 12 months; that beats the revenue growth of merely 3.1% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to CORMEDIX INC, a group of peers worth examining would be VHC, SERA, SLGC, XOS, and DYAI.
  • Visit CRMD's SEC page to see the company's official filings. To visit the company's web site, go to www.cormedix.com.

CRMD Valuation Summary

  • In comparison to the median Healthcare stock, CRMD's price/earnings ratio is 117.84% lower, now standing at -5.2.
  • Over the past 166 months, CRMD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CRMD.

Stock Date P/S P/B P/E EV/EBIT
CRMD 2023-12-29 6870.0 2.5 -5.2 -3.9
CRMD 2023-12-28 7070.0 2.5 -5.3 -4.0
CRMD 2023-12-27 7126.7 2.6 -5.4 -4.1
CRMD 2023-12-26 7163.3 2.6 -5.4 -4.1
CRMD 2023-12-22 6850.0 2.5 -5.2 -3.8
CRMD 2023-12-21 6596.7 2.4 -5.0 -3.7

CRMD Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 36.19%.
  • Its 2 year net cashflow from operations growth rate is now at -35.51%.
  • Its 2 year cash and equivalents growth rate is now at 267.79%.
Over the past 67 months, CRMD's revenue has gone down $130,133.

The table below shows CRMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.092103 -24.07125 -29.28374
2022-06-30 0.123374 -23.57935 -30.99939
2022-03-31 0.110312 -21.20875 -28.02748
2021-12-31 0.190936 -21.15522 -28.21023
2021-09-30 0.190254 -21.21935 -26.50618
2021-06-30 0.245186 -23.02867 -24.53757

CRMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRMD has a Quality Grade of F, ranking ahead of 0.4% of graded US stocks.
  • CRMD's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
  • ADAP, FBRX, and IDXX are the stocks whose asset turnover ratios are most correlated with CRMD.

The table below shows CRMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 0.132 -5.939
2021-03-31 0.005 0.141 -8.398
2020-12-31 0.007 0.144 -6.360
2020-09-30 0.007 0.070 -5.242
2020-06-30 0.006 -0.103 -3.741
2020-03-31 0.007 -0.006 -2.141

CRMD Price Target

For more insight on analysts targets of CRMD, see our CRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.25 Average Broker Recommendation 1.5 (Moderate Buy)

CorMedix Inc. (CRMD) Company Bio


CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.


CRMD Latest News Stream


Event/Time News Detail
Loading, please wait...

CRMD Latest Social Stream


Loading social stream, please wait...

View Full CRMD Social Stream

Latest CRMD News From Around the Web

Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

CorMedix Inc. Announces Appointment of Chief Legal Officer

BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no

Yahoo | December 15, 2023

CorMedix Inc. Announces Partnership With The Leapfrog Group

– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other pur

Yahoo | December 4, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

William White on InvestorPlace | November 15, 2023

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved DefenC

Yahoo | November 15, 2023

Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023

Net Loss Widens as Company Prepares for Potential FDA Approval of DefenCath

Yahoo | November 14, 2023

Read More 'CRMD' Stories Here

CRMD Price Returns

1-mo 14.80%
3-mo 7.95%
6-mo 4.68%
1-year 9.83%
3-year -61.81%
5-year -50.33%
YTD 1.06%
2023 -10.90%
2022 -7.25%
2021 -38.76%
2020 2.06%
2019 12.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!